Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics' stock price has increased significantly over the past six months and year. Positive earnings reports, decreased research and development expenses, and an extended cash runway have impacted the stock positively. Positive chronic cough trial results for Haduvio and a proposed public offering of $100 million in common stock have also contributed to investor confidence. Analyst sentiment is largely positive, with a consensus rating of "Moderate Buy" and a potential upside from its current price.

As a clinical-stage biopharmaceutical company, Trevi Therapeutics does not have commercialized products or services, so there is no traditional demand seasonality. The company's activities and financial performance are primarily driven by research and development milestones, clinical trial progress, regulatory approvals, and financing events.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid therapies for neurologically mediated conditions. Their primary product candidate, Haduvio, is being developed for chronic cough in patients with IPF, non-IPF interstitial lung disease, and refractory chronic cough, functioning as a KAMA targeting opioid receptors. While previously exploring Haduvio for severe skin conditions, the company has focused its pipeline on cough-related indications due to compelling clinical data.

Trevi Therapeutics, Inc. is based in New Haven, Connecticut, United States. The available information does not indicate a broader international geographic footprint for its operations or product commercialization at this clinical stage.

Trevi Therapeutics has maintained a positive brand reputation due to promising clinical trial results and favorable analyst coverage. The company's focus on developing Haduvio for chronic cough has been highlighted, particularly after positive Phase 2a results in refractory chronic cough. Analysts have issued positive ratings, suggesting strong market trust and a positive outlook for the company. News of advancing its cough treatment pipeline and securing substantial funding further contributes to a positive perception.

Institutional investors hold a significant stake in Trevi Therapeutics, Inc., possessing 52% of the company's shares, indicating their strong influence on the company. The total institutional ownership is reported to be 95.59% of total shares outstanding. Major institutional shareholders include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, BlackRock, Inc., and Vanguard Group Inc. Hedge funds own approximately 7.2% of Trevi Therapeutics shares. Insider ownership is under 1%, with board members holding no more than US$6.9 million worth of shares in the company. The general public holds about 22% ownership.